Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer

BACKGROUND: Cabazitaxel is approved for treatment of castration-resistant metastatic prostate cancer. The current dosing strategy of cabazitaxel is based on body surface area (BSA). Body surface area is known as a poor predictor for total systemic exposure to drugs, since it does not take into accou...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, A, Verkleij, C P M, van der Vlist, A, Mathijssen, R H J, Bloemendal, H J, ter Heine, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482735/
https://www.ncbi.nlm.nih.gov/pubmed/28399110
http://dx.doi.org/10.1038/bjc.2017.91

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482735/
https://www.ncbi.nlm.nih.gov/pubmed/28399110
http://dx.doi.org/10.1038/bjc.2017.91

Ejemplares similares